



Clinical trial results:

Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation (Intramuscular Route)

Summary

EudraCT number	2007-000752-14
Trial protocol	GB
Global end of trial date	03 July 2007

Results information

Result version number	v1 (current)
This version publication date	05 February 2016
First version publication date	03 December 2014

Trial information

Trial identification

Sponsor protocol code	GRT82
-----------------------	-------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00491257
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Sanofi Pasteur SA
Sponsor organisation address	1541, Avenue Marcel Mérieux, Marcy L'Etoile, France, 69280
Public contact	Director, Clinical Development, Sanofi Pasteur SA, 33 (0)4 37 37 58 43, emmanuel.feroldi@sanofipasteur.com
Scientific contact	Director, Clinical Development, Sanofi Pasteur SA, 33 (0)4 37 37 58 43, emmanuel.feroldi@sanofipasteur.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	25 July 2007
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	03 July 2007
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To check the compliance, in terms of immunogenicity, of the inactivated, split-virion influenza vaccine Northern Hemisphere 2007-2008 formulation with the requirements of the Committee for Human Medicinal Products (CHMP) Note for Guidance (NfG) CPMP/BWP/214/96.

Protection of trial subjects:

Only subjects who met all the study inclusion and none of the exclusion criteria were vaccinated in the study. Vaccinations were performed by qualified and trained study personnel. Subjects with allergy to any of the vaccine components were not vaccinated. After vaccination, subjects were also kept under clinical observation for 30 minutes to ensure their safety. Appropriate medical equipment were also available on site in case of any immediate allergic reactions.

Background therapy:

Not applicable

Evidence for comparator:

Not applicable

Actual start date of recruitment	11 June 2007
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 130
Worldwide total number of subjects	130
EEA total number of subjects	130

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	88

From 65 to 84 years	42
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Study subjects were enrolled and vaccinated on 11 June 2007 at 2 clinical centers in the United Kingdom.

Pre-assignment

Screening details:

A total of 130 subjects who met all inclusion criteria and none of the exclusion criteria were enrolled and vaccinated.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

Not applicable

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	18 to 60 years
------------------	----------------

Arm description:

Subjects aged 18 to 60 years who received one dose of inactivated, split-virion influenza vaccine, Northern Hemisphere 2007-2008 formulation on day 0.

Arm type	Experimental
Investigational medicinal product name	Influenza vaccine (split virion, inactivated)
Investigational medicinal product code	314
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

0.5 mL, intramuscular into the deltoid muscle, one dose on Day 0

Arm title	61 years or older
------------------	-------------------

Arm description:

Subjects aged 61 years or older who received one dose of inactivated, split-virion influenza vaccine, Northern Hemisphere 2007-2008 formulation on day 0.

Arm type	Experimental
Investigational medicinal product name	Influenza vaccine (split virion, inactivated)
Investigational medicinal product code	314
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

0.5 mL, intramuscular into the deltoid muscle, one dose on Day 0

Number of subjects in period 1	18 to 60 years	61 years or older
Started	65	65
Completed	64	65
Not completed	1	0
Lost to follow-up	1	-

Baseline characteristics

Reporting groups

Reporting group title	18 to 60 years
Reporting group description: Subjects aged 18 to 60 years who received one dose of inactivated, split-virion influenza vaccine, Northern Hemisphere 2007-2008 formulation on day 0.	
Reporting group title	61 years or older
Reporting group description: Subjects aged 61 years or older who received one dose of inactivated, split-virion influenza vaccine, Northern Hemisphere 2007-2008 formulation on day 0.	

Reporting group values	18 to 60 years	61 years or older	Total
Number of subjects	65	65	130
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	65	23	88
From 65-84 years	0	42	42
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	40.2	68.1	
standard deviation	± 12.75	± 5.04	-
Gender categorical			
Units: Subjects			
Female	28	31	59
Male	37	34	71
Previous influenza vaccination			
Units: Subjects			
Yes	20	51	71
No	45	14	59
Previous influenza infection last winter			
Units: Subjects			
Yes	3	1	4
No	62	64	126

End points

End points reporting groups

Reporting group title	18 to 60 years
Reporting group description:	
Subjects aged 18 to 60 years who received one dose of inactivated, split-virion influenza vaccine, Northern Hemisphere 2007-2008 formulation on day 0.	
Reporting group title	61 years or older
Reporting group description:	
Subjects aged 61 years or older who received one dose of inactivated, split-virion influenza vaccine, Northern Hemisphere 2007-2008 formulation on day 0.	

Primary: Summary of Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation by the Intramuscular Route

End point title	Summary of Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation by the Intramuscular Route ^[1]
End point description:	
Influenza vaccine antibodies were assessed using the hemagglutination inhibition technique.	
End point type	Primary
End point timeframe:	
Day 0 (pre-vaccination) and Day 21 post vaccination	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 60 years	61 years or older		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	63	65		
Units: Titers				
geometric mean (confidence interval 95%)				
Flu A/SolomonIslands/3/2006 (H1N1; Day 0)	10.9 (8.2 to 14.5)	13.1 (9.86 to 17.3)		
Flu A/Wisconsin/67/2005 (H3N2; Day 0)	24.8 (16.8 to 36.5)	58.1 (38.5 to 87.7)		
Flu B/Malaysia/2506/2004 (B native; Day 0)	7.07 (6.07 to 8.24)	10.3 (8.4 to 12.7)		
Flu B/Malaysia/2506/2004 (B split; Day 0)	11.8 (9.58 to 14.5)	26.2 (20.6 to 33.4)		
Flu A/SolomonIslands/3/2006 (H1N1; Day 21)	311 (221 to 439)	134 (95.9 to 188)		
Flu A/Wisconsin/67/2005 (H3N2; Day 21)	445 (326 to 608)	225 (163 to 310)		
Flu B/Malaysia/2506/2004 (B native; Day 21)	46.2 (34.3 to 62)	24.5 (19.4 to 31)		
Flu B/Malaysia/2506/2004 (B split; Day 21)	116 (96.4 to 139)	74.2 (62.6 to 88)		

Statistical analyses

No statistical analyses for this end point

Primary: Summary of Geometric Mean Titters Ratios (GMTR) of Influenza Vaccine Antibodies After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation by the Intramuscular Route

End point title	Summary of Geometric Mean Titters Ratios (GMTR) of Influenza Vaccine Antibodies After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation by the Intramuscular Route ^[2]
-----------------	---

End point description:

Influenza vaccine antibodies were assessed using the hemagglutination inhibition technique. Geometric mean titer ratio is the geometric mean of the individual post-vaccination/pre-vaccination titer of antibodies to the influenza virus antigens.

End point type	Primary
----------------	---------

End point timeframe:

Day 0 (pre-vaccination) and Day 21 post vaccination

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 60 years	61 years or older		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	63	65		
Units: Titer ratios				
geometric mean (confidence interval 95%)				
Flu A/SolomonIslands/3/2006 (H1N1)	28.5 (19.2 to 42.3)	10.3 (7.02 to 15)		
Flu A/Wisconsin/67/2005 (H3N2)	18 (11.5 to 28)	3.87 (2.64 to 5.68)		
Flu B/Malaysia/2506/2004 (B native)	6.53 (4.88 to 8.73)	2.37 (1.93 to 2.91)		
Flu B/Malaysia/2506/2004 (B split)	9.81 (7.32 to 13.1)	2.83 (2.27 to 3.53)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects with Seroprotection Against the Influenza Vaccine Antigens Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation by the Intramuscular Route

End point title	Percentage of Subjects with Seroprotection Against the
-----------------	--

End point description:

Influenza vaccine antibodies were assessed using the hemagglutination inhibition technique. Seroconversion was defined as titers ≥ 40 (1/dil) on Day 0 and Day 21.

End point type Primary

End point timeframe:

Day 0 (pre-vaccination) and Day 21 post vaccination

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 60 years	61 years or older		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	63	65		
Units: Percentage of subjects				
number (not applicable)				
Flu A/SolomonIslands/3/2006 (H1N1; Day 0)	19	20		
Flu A/Wisconsin/67/2005 (H3N2; Day 0)	42.9	56.9		
Flu B/Malaysia/2506/2004 (B native; Day 0)	4.8	10.8		
Flu B/Malaysia/2506/2004 (B split; Day 0)	7.9	44.6		
Flu A/SolomonIslands/3/2006 (H1N1; Day 21)	98.4	87.7		
Flu A/Wisconsin/67/2005 (H3N2; Day 21)	98.4	93.8		
Flu B/Malaysia/2506/2004 (B native; Day 21)	60.3	40		
Flu B/Malaysia/2506/2004 (B split; Day 21)	93.7	84.6		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Achieving Seroconversion or Significant Increase Against the Influenza Vaccine Antigens Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation by Intramuscular Route

End point title	Percentage of Subjects Achieving Seroconversion or Significant Increase Against the Influenza Vaccine Antigens Before and After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation by Intramuscular Route ^[4]
-----------------	---

End point description:

Influenza vaccine antibodies were assessed using the hemagglutination inhibition technique. Seroconversion was defined as subjects with a titer < 10 (1/dil) on Day 0 and a post-injection titer ≥ 40 (1/dil) on Day 21 or significant increase was defined as subjects with a titer ≥ 10 (1/dil) on Day 0 and a ≥ 4 -fold increase from pre- to post-injection titer on Day 21.

End point type	Primary
End point timeframe:	
Day 21 post vaccination	
Notes:	
[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.	

End point values	18 to 60 years	61 years or older		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	63	65		
Units: Percentage of subjects				
number (not applicable)				
Flu A/SolomonIslands/3/2006 (H1N1)	88.9	66.2		
Flu A/Wisconsin/67/2005 (H3N2)	81	36.9		
Flu B/Malaysia/2506/2004 (B native)	54	20		
Flu B/Malaysia/2506/2004 (B split)	81	26.2		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects with at Least One Reaction Corresponding to those Listed in the EMEA Recommendation Within 3 Days After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation by Intramuscular Route

End point title	Percentage of Subjects with at Least One Reaction Corresponding to those Listed in the EMEA Recommendation Within 3 Days After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation by Intramuscular Route ^[5]
-----------------	--

End point description:

Solicited injection site: Induration and Ecchymosis. Solicited systemic reactions: Temperature, Malaise, and Shivering.

End point type	Primary
End point timeframe:	
Day 0 up to Day 3 post-vaccination	

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 60 years	61 years or older		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	65		
Units: Percentage of subjects				
number (not applicable)				
Injection site induration >5 cm for >3 days	0	0		
Injection site ecchymosis	10.9	4.6		

Temperature >38°C for ≥24 hours	0	0		
Malaise	17.2	6.2		
Shivering	6.3	4.6		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting Solicited Injection-site or Systemic Reactions Within 3 Days After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation by the Intramuscular Route

End point title	Percentage of Subjects Reporting Solicited Injection-site or Systemic Reactions Within 3 Days After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation by the Intramuscular Route ^[6]
-----------------	---

End point description:

Solicited injection site: Pain, Erythema, Swelling, Induration and Ecchymosis. Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Shivering. Grade 3 injection site: Pain – Incapacitating, unable to perform usual activities; Erythema, Swelling, Induration, and Ecchymosis – ≥5 cm. Grade 3 systemic reactions: Fever – >39.0°C; Headache, Malaise, Myalgia, and Shivering – Prevents daily activities.

End point type	Primary
----------------	---------

End point timeframe:

Day 0 up to Day 3 post-vaccination

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 60 years	61 years or older		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	65		
Units: Percentage of subjects				
number (not applicable)				
Injection site Pain	39.1	24.6		
Grade 3 Injection site Pain	0	0		
Injection site Erythema	9.4	10.8		
Grade 3 Injection site Erythema	1.6	4.6		
Injection site Swelling	12.5	12.3		
Grade 3 Injection site Swelling	1.6	1.5		
Injection site Induration	15.6	9.2		
Grade 3 Injection site Induration	1.6	0		
Injection site Ecchymosis	10.9	4.6		
Grade 3 Injection site Ecchymosis	0	0		
Fever	1.6	0		
Grade 3 Fever	0	0		
Headache	26.6	16.9		
Grade 3 Headache	4.7	1.5		
Malaise	17.2	6.2		
Grade 3 Malaise	1.6	1.5		

Myalgia	23.4	10.8		
Grade 3 Myalgia	1.6	0		
Shivering	6.3	4.6		
Grade 3 Shivering	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects Reporting Solicited Injection-site or Systemic Reactions More than 3 Days After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation by the Intramuscular Route

End point title	Percentage of Subjects Reporting Solicited Injection-site or Systemic Reactions More than 3 Days After Vaccination with Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation by the Intramuscular Route ^[7]
-----------------	--

End point description:

Solicited injection site: Pain, Erythema, Swelling, Induration and Ecchymosis. Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Shivering. Grade 3 injection site: Pain – Incapacitating, unable to perform usual activities; Erythema, Swelling, Induration, and Ecchymosis – ≥5 cm. Grade 3 systemic reactions: Fever – >39.0°C; Headache, Malaise, Myalgia, and Shivering – Prevents daily activities.

End point type	Primary
----------------	---------

End point timeframe:

>Day 3 post vaccination

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 60 years	61 years or older		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	65	65		
Units: Percentage of subjects				
number (not applicable)				
Injection site Pain	0	0		
Grade 3 Injection site Pain	0	0		
Injection site Erythema	0	0		
Grade 3 Injection site Erythema	0	0		
Injection site Swelling	0	0		
Grade 3 Injection site Swelling	0	0		
Injection site Induration	0	0		
Grade 3 Injection site Induration	0	0		
Injection site Ecchymosis	0	0		
Grade 3 Injection site Ecchymosis	0	0		
Fever	0	0		
Grade 3 Fever	0	0		
Headache	1.6	0		
Grade 3 Headache	0	0		

Malaise	0	1.5		
Grade 3 Malaise	0	0		
Myalgia	0	3.1		
Grade 3 Myalgia	0	0		
Shivering	0	0		
Grade 3 Shivering	0	0		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse event data were collected from Day 0 (post-vaccination) up to Day 21 post-vaccination.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	9.0
--------------------	-----

Reporting groups

Reporting group title	18 to 60 years
-----------------------	----------------

Reporting group description:

Subjects aged 18 to 60 years who received one dose of inactivated, split-virion influenza vaccine, Northern Hemisphere 2007-2008 formulation on day 0.

Reporting group title	61 years or older
-----------------------	-------------------

Reporting group description:

Subjects aged 61 years or older who received one dose of inactivated, split-virion influenza vaccine, Northern Hemisphere 2007-2008 formulation on day 0.

Serious adverse events	18 to 60 years	61 years or older	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 65 (0.00%)	0 / 65 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	18 to 60 years	61 years or older	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	25 / 65 (38.46%)	16 / 65 (24.62%)	
Nervous system disorders			
Headache			
alternative assessment type: Systematic			
subjects affected / exposed ^[1]	17 / 64 (26.56%)	11 / 65 (16.92%)	
occurrences (all)	17	11	
General disorders and administration site conditions			
Injection site ecchymosis			
alternative assessment type: Systematic			

subjects affected / exposed ^[2]	7 / 64 (10.94%)	3 / 65 (4.62%)	
occurrences (all)	7	3	
Malaise			
alternative assessment type: Systematic			
subjects affected / exposed ^[3]	11 / 64 (17.19%)	4 / 65 (6.15%)	
occurrences (all)	11	4	
Shivering			
alternative assessment type: Systematic			
subjects affected / exposed ^[4]	4 / 64 (6.25%)	3 / 65 (4.62%)	
occurrences (all)	4	3	
Injection site pain			
alternative assessment type: Systematic			
subjects affected / exposed ^[5]	25 / 64 (39.06%)	16 / 65 (24.62%)	
occurrences (all)	25	16	
Injection site erythema			
alternative assessment type: Systematic			
subjects affected / exposed ^[6]	6 / 64 (9.38%)	7 / 65 (10.77%)	
occurrences (all)	6	7	
Injection site swelling			
alternative assessment type: Systematic			
subjects affected / exposed ^[7]	8 / 64 (12.50%)	8 / 65 (12.31%)	
occurrences (all)	8	8	
Injection site induration			
alternative assessment type: Systematic			
subjects affected / exposed ^[8]	10 / 64 (15.63%)	6 / 65 (9.23%)	
occurrences (all)	10	6	
Musculoskeletal and connective tissue disorders			
Myalgia			
alternative assessment type: Systematic			
subjects affected / exposed ^[9]	15 / 64 (23.44%)	7 / 65 (10.77%)	
occurrences (all)	15	7	

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: This was a solicited adverse event recorded in a diary card within 3 days of vaccination; the total number (N) reflects those subjects for which the diary cards were returned and for which data

were available for the event during the period.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: This was a solicited adverse event recorded in a diary card within 3 days of vaccination; the total number (N) reflects those subjects for which the diary cards were returned and for which data were available for the event during the period.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: This was a solicited adverse event recorded in a diary card within 3 days of vaccination; the total number (N) reflects those subjects for which the diary cards were returned and for which data were available for the event during the period.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: This was a solicited adverse event recorded in a diary card within 3 days of vaccination; the total number (N) reflects those subjects for which the diary cards were returned and for which data were available for the event during the period.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: This was a solicited adverse event recorded in a diary card within 3 days of vaccination; the total number (N) reflects those subjects for which the diary cards were returned and for which data were available for the event during the period.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: This was a solicited adverse event recorded in a diary card within 3 days of vaccination; the total number (N) reflects those subjects for which the diary cards were returned and for which data were available for the event during the period.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: This was a solicited adverse event recorded in a diary card within 3 days of vaccination; the total number (N) reflects those subjects for which the diary cards were returned and for which data were available for the event during the period.

[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: This was a solicited adverse event recorded in a diary card within 3 days of vaccination; the total number (N) reflects those subjects for which the diary cards were returned and for which data were available for the event during the period.

[9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: This was a solicited adverse event recorded in a diary card within 3 days of vaccination; the total number (N) reflects those subjects for which the diary cards were returned and for which data were available for the event during the period.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported